Teladoc Health’s (TDOC) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Teladoc Health (NYSE:TDOC) in a report released on Thursday morning,Benzinga reports.

Several other research firms have also weighed in on TDOC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Citigroup dropped their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday, August 3rd. Bank of America raised their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Finally, Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Teladoc Health currently has an average rating of “Hold” and an average price target of $7.77.

Teladoc Health Trading Down 2.4%

Shares of Teladoc Health stock opened at $8.52 on Thursday. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $9.89. The stock has a market capitalization of $1.55 billion, a P/E ratio of -9.91 and a beta of 2.14. The business’s fifty day moving average price is $6.23 and its 200 day moving average price is $6.47.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $605.10 million during the quarter, compared to the consensus estimate of $588.14 million. Teladoc Health had a negative return on equity of 11.52% and a negative net margin of 6.27%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.28) earnings per share. As a group, sell-side analysts predict that Teladoc Health will post -0.89 EPS for the current year.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares in the company, valued at $2,839,763.50. This represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.

Institutional Trading of Teladoc Health

Several large investors have recently bought and sold shares of TDOC. Mirae Asset Global Investments Co. Ltd. purchased a new position in Teladoc Health in the third quarter valued at about $60,000. Vise Technologies Inc. increased its holdings in Teladoc Health by 26.5% during the 3rd quarter. Vise Technologies Inc. now owns 22,035 shares of the health services provider’s stock worth $128,000 after purchasing an additional 4,614 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Teladoc Health by 9.5% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 186,825 shares of the health services provider’s stock worth $1,084,000 after purchasing an additional 16,200 shares during the last quarter. Partners Wealth Management LLC purchased a new stake in Teladoc Health during the 3rd quarter worth approximately $58,000. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Teladoc Health by 11.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 206,625 shares of the health services provider’s stock valued at $1,198,000 after buying an additional 21,334 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
• Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
• Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
• Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
• Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
• Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.